1. Rational Helicobacter pylori Therapy: Evidence-Based Medicine Rather Than Medicine- Based Evidence 
David Y. Graham, Yi–Chia Lee, Ming–Shiang Wu 
Clinical Gastroenterology and Hepatology 
Volume 12, Issue 2, Pages e3 (February 2014)
DOI: /j.cgh
Copyright © Terms and Conditions

2. Figure 1
Recommended approach to treatment of H pylori infections. Rx, treatment.
Clinical Gastroenterology and Hepatology  , e3DOI: ( /j.cgh )
Copyright © Terms and Conditions

3. Figure 2
Example of choices of clarithromycin-containing regimens for an individual patient based on predicted resistance to clarithomycin and metronidazole.
Clinical Gastroenterology and Hepatology  , e3DOI: ( /j.cgh )
Copyright © Terms and Conditions

4. Supplementary Figure 1
The effect of increasing metronidazole and clarithromycin resistance and the prevalence of dual clarithromycin-metronidazole resistance. When dual resistance equals 15% (dotted line), then 14-day concomitant therapy will cure less than 90% of patients. The proportion of patients with dual resistance is shown at different prevalences of metronidazole resistance, with the proportion with dual resistance plotted against the prevalence of clarithromycin resistance. As long as metronidazole resistance levels are less than 40%, the regimen is very resistant to typical increases in clarithromycin resistance. However, at high levels of resistance of either, only modest levels of resistance of the other will result in dual resistance exceeding the threshold level for treatment failure.
Clinical Gastroenterology and Hepatology  , e3DOI: ( /j.cgh )
Copyright © Terms and Conditions